TY - JOUR
AU - Dimakakos, Evangelos
AU - Gomatou, Georgia
AU - Catalano, Mariella
AU - Olinic, Dan-Mircea
AU - Spyropoulos, Alex C.
AU - Falanga, Anna
AU - Maraveyas, Anthony
AU - Liew, Aaron
AU - Schulman, Sam
AU - Belch, Jill
AU - Gerotziafas, Grigorios T.
AU - Marschang, Peter
AU - Cosmi, Benilde
AU - Spaak, Jonas
AU - Syrigos, Konstantinos
AU - Cancer-Covid-19 Thrombosis Collaborative Group
PY - 2022
DA - July
TI - Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art
JO - Anticancer Research
EP - 3274
VL - 42
IS - 7
DO - https://doi.org/10.21873/anticanres.15815
AB - Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currentlyindicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARS-CoV2 remains unclear In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist.
PB - International Institute of Anticancer Research
UR - https://discovery.dundee.ac.uk/en/publications/b020404e-82ba-4f4c-91ec-4a877a1c7695
KW - Coronavirus (COVID-19)
ER